Jazz Pharmaceuticals announced on October 23, 2025, the appointment of Dr. Ted Love to its Board of Directors, effective December 1, 2025135.
Dr. Love will serve as a Class I director, with his term expiring at the 2027 annual general meeting27.
He will join the Audit Committee and Science and Medicine Committee of the Board2.
Dr. Love brings over 30 years of drug development and executive leadership experience, notably as the former CEO of Global Blood Therapeutics45.
He will receive cash and equity compensation per the company's standard non-employee director program, and sign Jazz's standard indemnification agreement2.
Kenneth W. O’Keefe will retire from the Board on December 1, 2025; his retirement is not due to any dispute or disagreement with the company2.
Sources:
1. https://www.tipranks.com/news/company-announcements/jazz-pharmaceuticals-appoints-dr-ted-love-to-board
2. https://www.stocktitan.net/sec-filings/JAZZ/8-k-jazz-pharmaceuticals-plc-reports-material-event-17b5cf8dd031.html
3. https://www.tradingview.com/news/tradingview:3fc0a57647277:0-jazz-pharmaceuticals-announces-board-changes/
4. https://www.moomoo.com/news/post/60427719?futusource=nnqpersonalguest
5. https://www.streetinsider.com/Board+Changes/Jazz+Pharmaceuticals+adds+former+Global+Blood+Therapeutics+CEO+to+board/25513412.html
7. https://www.sec.gov/Archives/edgar/data/1232524/000162828025046763/jazz-20251023.htm